Publication | Closed Access

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

MedicinePharmacologyClinical TrialsColorectal CancerMetastatic Colorectal CancerVersus FolfiriPharmacotherapyAnti-cancer AgentCancer TreatmentSecond-line TherapyOncologyRadiation OncologyHealth Sciences